Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Jade Biosciences (JBIO), Elevance Health (ELV) and Regeneron (REGN)

Tipranks - Tipranks - Fri Apr 24, 4:42AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jade Biosciences (JBIO), Elevance Health (ELV) and Regeneron (REGN).

Claim 30% Off TipRanks

Jade Biosciences (JBIO)

William Blair analyst Matt Phipps maintained a Buy rating on Jade Biosciences today. The company’s shares closed last Wednesday at $25.38.

According to TipRanks.com, Phipps is a 4-star analyst with an average return of 5.1% and a 44.3% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Bristol-Myers Squibb. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jade Biosciences with a $30.83 average price target.

See today’s best-performing stocks on TipRanks >>

Elevance Health (ELV)

In a report released today, Kevin Fischbeck from Bank of America Securities reiterated a Hold rating on Elevance Health, with a price target of $405.00. The company’s shares closed last Wednesday at $328.20.

According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of 2.8% and a 58.1% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Molina Healthcare, and Tenet Healthcare. ;'>

Currently, the analyst consensus on Elevance Health is a Moderate Buy with an average price target of $377.59, which is an 11.8% upside from current levels. In a report issued on April 8, Evercore ISI also initiated coverage with a Hold rating on the stock with a $345.00 price target.

Regeneron (REGN)

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Regeneron, with a price target of $860.00. The company’s shares closed last Wednesday at $746.58.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 3.0% and a 53.6% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Bicara Therapeutics Inc. ;'>

Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $874.76, implying a 16.4% upside from current levels. In a report issued on April 8, Bernstein also maintained a Buy rating on the stock with a $921.00 price target.

Read More on JBIO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).